Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)
Clinical trial NCT04364230 · COMPLETED
Trial details
- NCT number
- NCT04364230
- Sponsor
- Craig L Slingluff, Jr
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-28
- Primary completion
- 2024-03-14
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.